In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A

Gianni Marone, Amato de Paulis, Vincenzo Casolaro, Anna Ciccarelli, Giuseppe Spadaro, Raffaele Cirillo

Research output: Contribution to journalArticle

Abstract

Cyclosporin A (CsA), a cyclic undecapeptide extracted from Tolypocladium inflatum Gams, is effective in the prevention/treatment of graft rejection and in an increasing number of autoimmune and inflammatory disorders. The immunosuppressive effect of CsA was initially attributed to inhibition of lym- phokine mRNA transcription. We have demonstrated that pharmacological concentrations of CsA (10-100 ng/ml) also inhibit the in vitro immunologic release of preformed (histamine) and de novo synthesized (leukotriene C4 and prostaglandin D2) mediators of inflammatory reactions from human basophils and mast cells. Furthermore, the administration of a single dose of CsA (7 mg/ kg) to 8 normal donors caused a rapid and significant (20-40%) inhibition of histamine release from basophils obtained ex vivo from these subjects and challenged in vitro with anti-IgE, f-Met-Leu-Phe and A23187. The inhibitory effect of CsA peaked at 1-5 h, slowly decreased up to 13 h, and was associated with a sharp increase in blood CsA levels. Thus, CsA exerts remarkable anti-inflammatory effects on the immunologic release of mediators from human basophils and mast cells - properties that may contribute to the drug’s ther-apeutic effects.

Original languageEnglish (US)
Pages (from-to)279-283
Number of pages5
JournalInternational Archives of Allergy and Immunology
Volume99
Issue number2-4
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Cyclosporine
Anti-Inflammatory Agents
Basophils
Histamine Release
Mast Cells
methionyl-leucyl-phenylalanine
Prostaglandin D2
Leukotriene C4
Lymphokines
Calcimycin
Graft Rejection
Immunosuppressive Agents
In Vitro Techniques
Pharmacology
Messenger RNA
Pharmaceutical Preparations

Keywords

  • Basophils
  • Cyclosporin A
  • Histamine
  • Leukotriene C<inf>4</inf>
  • Mast cells
  • Prostaglandin D<inf>2</inf>

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Marone, G., de Paulis, A., Casolaro, V., Ciccarelli, A., Spadaro, G., & Cirillo, R. (1992). In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A. International Archives of Allergy and Immunology, 99(2-4), 279-283. https://doi.org/10.1159/000236265

In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A. / Marone, Gianni; de Paulis, Amato; Casolaro, Vincenzo; Ciccarelli, Anna; Spadaro, Giuseppe; Cirillo, Raffaele.

In: International Archives of Allergy and Immunology, Vol. 99, No. 2-4, 1992, p. 279-283.

Research output: Contribution to journalArticle

Marone, G, de Paulis, A, Casolaro, V, Ciccarelli, A, Spadaro, G & Cirillo, R 1992, 'In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A', International Archives of Allergy and Immunology, vol. 99, no. 2-4, pp. 279-283. https://doi.org/10.1159/000236265
Marone, Gianni ; de Paulis, Amato ; Casolaro, Vincenzo ; Ciccarelli, Anna ; Spadaro, Giuseppe ; Cirillo, Raffaele. / In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A. In: International Archives of Allergy and Immunology. 1992 ; Vol. 99, No. 2-4. pp. 279-283.
@article{41542aa4643b4ad3a290f519bf6895b0,
title = "In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A",
abstract = "Cyclosporin A (CsA), a cyclic undecapeptide extracted from Tolypocladium inflatum Gams, is effective in the prevention/treatment of graft rejection and in an increasing number of autoimmune and inflammatory disorders. The immunosuppressive effect of CsA was initially attributed to inhibition of lym- phokine mRNA transcription. We have demonstrated that pharmacological concentrations of CsA (10-100 ng/ml) also inhibit the in vitro immunologic release of preformed (histamine) and de novo synthesized (leukotriene C4 and prostaglandin D2) mediators of inflammatory reactions from human basophils and mast cells. Furthermore, the administration of a single dose of CsA (7 mg/ kg) to 8 normal donors caused a rapid and significant (20-40{\%}) inhibition of histamine release from basophils obtained ex vivo from these subjects and challenged in vitro with anti-IgE, f-Met-Leu-Phe and A23187. The inhibitory effect of CsA peaked at 1-5 h, slowly decreased up to 13 h, and was associated with a sharp increase in blood CsA levels. Thus, CsA exerts remarkable anti-inflammatory effects on the immunologic release of mediators from human basophils and mast cells - properties that may contribute to the drug’s ther-apeutic effects.",
keywords = "Basophils, Cyclosporin A, Histamine, Leukotriene C<inf>4</inf>, Mast cells, Prostaglandin D<inf>2</inf>",
author = "Gianni Marone and {de Paulis}, Amato and Vincenzo Casolaro and Anna Ciccarelli and Giuseppe Spadaro and Raffaele Cirillo",
year = "1992",
doi = "10.1159/000236265",
language = "English (US)",
volume = "99",
pages = "279--283",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2-4",

}

TY - JOUR

T1 - In vitro and in vivo characterization of the anti- inflammatory effects of cyclosporin A

AU - Marone, Gianni

AU - de Paulis, Amato

AU - Casolaro, Vincenzo

AU - Ciccarelli, Anna

AU - Spadaro, Giuseppe

AU - Cirillo, Raffaele

PY - 1992

Y1 - 1992

N2 - Cyclosporin A (CsA), a cyclic undecapeptide extracted from Tolypocladium inflatum Gams, is effective in the prevention/treatment of graft rejection and in an increasing number of autoimmune and inflammatory disorders. The immunosuppressive effect of CsA was initially attributed to inhibition of lym- phokine mRNA transcription. We have demonstrated that pharmacological concentrations of CsA (10-100 ng/ml) also inhibit the in vitro immunologic release of preformed (histamine) and de novo synthesized (leukotriene C4 and prostaglandin D2) mediators of inflammatory reactions from human basophils and mast cells. Furthermore, the administration of a single dose of CsA (7 mg/ kg) to 8 normal donors caused a rapid and significant (20-40%) inhibition of histamine release from basophils obtained ex vivo from these subjects and challenged in vitro with anti-IgE, f-Met-Leu-Phe and A23187. The inhibitory effect of CsA peaked at 1-5 h, slowly decreased up to 13 h, and was associated with a sharp increase in blood CsA levels. Thus, CsA exerts remarkable anti-inflammatory effects on the immunologic release of mediators from human basophils and mast cells - properties that may contribute to the drug’s ther-apeutic effects.

AB - Cyclosporin A (CsA), a cyclic undecapeptide extracted from Tolypocladium inflatum Gams, is effective in the prevention/treatment of graft rejection and in an increasing number of autoimmune and inflammatory disorders. The immunosuppressive effect of CsA was initially attributed to inhibition of lym- phokine mRNA transcription. We have demonstrated that pharmacological concentrations of CsA (10-100 ng/ml) also inhibit the in vitro immunologic release of preformed (histamine) and de novo synthesized (leukotriene C4 and prostaglandin D2) mediators of inflammatory reactions from human basophils and mast cells. Furthermore, the administration of a single dose of CsA (7 mg/ kg) to 8 normal donors caused a rapid and significant (20-40%) inhibition of histamine release from basophils obtained ex vivo from these subjects and challenged in vitro with anti-IgE, f-Met-Leu-Phe and A23187. The inhibitory effect of CsA peaked at 1-5 h, slowly decreased up to 13 h, and was associated with a sharp increase in blood CsA levels. Thus, CsA exerts remarkable anti-inflammatory effects on the immunologic release of mediators from human basophils and mast cells - properties that may contribute to the drug’s ther-apeutic effects.

KW - Basophils

KW - Cyclosporin A

KW - Histamine

KW - Leukotriene C<inf>4</inf>

KW - Mast cells

KW - Prostaglandin D<inf>2</inf>

UR - http://www.scopus.com/inward/record.url?scp=0027074399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027074399&partnerID=8YFLogxK

U2 - 10.1159/000236265

DO - 10.1159/000236265

M3 - Article

AN - SCOPUS:0027074399

VL - 99

SP - 279

EP - 283

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2-4

ER -